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  ABSTRACT 
  Objectives      To create a model that provides a potential 
basis for candidate selection for anti-tumour necrosis 
factor (TNF) treatment by predicting future outcomes 
relative to the current disease proﬁ  le of individual patients 
with ankylosing spondylitis (AS).   
  Methods      ASSERT and GO–RAISE trial data (n=635) 
were analysed to identify baseline predictors for various 
disease-state and disease-activity outcome instruments 
in AS. Univariate, multivariate, receiver operator 
characteristic and correlation analyses were performed to 
select ﬁ  nal predictors. Their associations with outcomes 
were explored. Matrix and algorithm-based prediction 
models were created using logistic and linear regression, 
and their accuracies were compared. Numbers needed 
to treat were calculated to compare the effect size of 
anti-TNF therapy between the AS matrix subpopulations. 
Data from registry populations were applied to study 
how a daily practice AS population is distributed over the 
prediction model.   
  Results      Age, Bath ankylosing spondylitis functional 
index (BASFI) score, enthesitis, therapy, C-reactive 
protein (CRP) and HLA-B27 genotype were identiﬁ  ed 
as predictors. Their associations with each outcome 
instrument varied. However, the combination of these 
factors enabled adequate prediction of each outcome 
studied. The matrix model predicted outcomes as well as 
algorithm-based models and enabled direct comparison 
of the effect size of anti-TNF treatment outcome in 
various subpopulations. The trial populations reﬂ  ected the 
daily practice AS population.   
  Conclusion      Age, BASFI, enthesitis, therapy, CRP and 
HLA-B27 were associated with outcomes in AS. Their 
combined use enables adequate prediction of outcome 
resulting from anti-TNF and conventional therapy in 
various AS subpopulations. This may help guide clinicians 
in making treatment decisions in daily practice.           
  Ankylosing spondylitis (AS) is characterised by 
back pain caused by inﬂ   ammation of the sacro-
iliac joints and spine. The management of AS 
includes non-pharmacological, pharmacological, 
invasive and surgical interventions that should be 
tailored to each patient’s disease manifestations, 
current symptoms, clinical ﬁ  ndings and prognostic 
  indicators.    1    Non-steroidal anti-inﬂ  ammatory drugs 
(NSAID) are recommended as ﬁ  rst-line  pharma-
cological treatment, and anti-tumour necrosis fac-
tor (TNF) agents are recommended in the case of 
NSAID failure.    2     –      6    
  Predictors of response to therapy may enable 
improved patient selection, outcomes and resource 
utilisation.    7        8    The recommendations for anti-TNF 
use in AS are, however, based primarily on inad-
equate response to conventional therapies and less 
on the expectation that an anti-TNF agent will 
be effective in a particular patient.    2    The literature 
continues to establish predictors of response,    9     –      14    
which are also associated with anti-TNF use in 
AS.    15    Ideally, these may help clinicians to make 
evidence-based decisions that maximise the bene-
ﬁ  ts from treatment by targeting subsets of patients 
most likely to respond;    16    however, single predictors 
are too weak to be useful for decision-making in 
the individual patient. 
  This paper describes the predictor selection 
and construction of a model that identiﬁ  es  AS 
subpopulations likely to respond optimally to 
anti-TNF therapy. In the absence of a ‘hard out-
come’ parameter that can be predicted in AS, such 
as mortality in cardiovascular disease, the ability 
and robustness of the predictor model to predict 
the results of a variety of AS outcome instruments 
were explored. 
  In addition, the distribution of AS registry popu-
lations encountered in daily rheumatology practice 
over the prediction model was evaluated. 
  PATIENTS  AND  METHODS 
  This is a post-hoc analysis of the ASSERT and 
GO–RAISE trials in adult patients with active AS 
despite NSAID or disease-modifying antirheumatic 
drugs (DMARD) and naive to anti-TNF therapy. 
  In ASSERT, patients were randomly assigned to 
receive infusions of placebo or 5 mg/kg inﬂ  iximab 
at weeks 0, 2, 6, 12 and 18 and were allowed to 
receive concurrent NSAID but not DMARD or 
systemic corticosteroids.    5    In GO–RAISE, patients 
were randomly assigned to receive subcutaneous 
injections of placebo or 50 or 100 mg golimumab 
every 4 weeks and could continue concurrent 
NSAID, DMARD and systemic corticosteroids. 
For our analysis, week 16 data from GO–RAISE 
were carried forward to week 24 for placebo 
patients who received golimumab starting at 
week 16.    4    Week 24 data were collected between 
November 2002 and September 2003 in ASSERT 
and between December 2005 and May 2007 in 
GO–RAISE. 
  Outcome  instruments 
  The Bath ankylosing spondylitis disease activ-
ity index (BASDAI) score measures disease activ-
ity based on six questions on fatigue, spinal pain, 
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association; 2.5 to 1 moderate association; 4 to 1 strong associa-
tion and 10 to 1 very strong association.    24      
  Matrix  model  construction 
  Fitted logistic regression was used to calculate the predicted 
proportion of patients meeting the outcome criterion accord-
ing to each subpopulation’s value category for the predictors 
at baseline. These results were organised into a matrix model 
showing increasing predicted rates of achieving each outcome 
from left to right, bottom to top.    25    Patient subpopulations with 
high predicted outcome rates are shown in yellow, those with 
low rates are shown in red, and those with intermediate rates 
are shown in orange. The numbers needed to treat (NNT) to 
realise a target beneﬁ   cial outcome following anti-TNF treat-
ment was calculated as follows: NNT=1/(predicted outcome 
rate with anti-TNF–predicted outcome rate with conventional 
therapy) and are presented in matrix models using a white, grey 
and black colour scheme.   
  Algorithm-based  models 
  For each outcome instrument, logistic regression with stepwise 
selection was used to calculate the model yielding the highest 
ROC–AUC and R  2   using numeric values for CRP, BASFI, age 
and enthesitis score; categorical values for treatment and HLA-
B27 genotype and their interaction terms. In a similar approach 
using linear regression, models predicting week 12 ASDAS and 
BASDAI scores were also calculated. The multiple correlation 
coefﬁ  cient (R), which represents the correlation between the 
observed and the predicted values, and the R  2   were calculated, 
with R of 0.1 or less being ‘small’, R of 0.1−0.3 being ‘medium’, 
and R of 0.3−0.5 being ‘large’.    26    The predicted versus the 
observed change in ASDAS and BASDAI scores were plotted.     
    Distribution of two registry AS populations over the prediction 
model 
  The ASPECT and the Regisponser studies    15        27        28    conducted 
in 2004–5 in Belgium and Spain, respectively, were used to 
study the distribution of a daily practice AS population over 
the model. Cross-sectional data were used from AS patients 
who had complete data for BASDAI, BASFI, CRP, the presence 
of enthesitis, age and HLA-B27 status. The percentage of the 
ASPECT/Regisponser populations falling within each of the 
predictor value categories in the matrix model is shown for all 
patients, irrespective of BASDAI score (total registry popula-
tion), and only for patients with a BASDAI score of 4 or greater 
(active registry population). The proportion of registry patients 
corresponding with the NNT categories in the matrix models for 
various outcome instruments is reported. The OR of BASDAI50 
response in the combined dataset were compared with those 
reported for AS populations treated with anti-TNF therapy in 
clinical practice.    10     –      12        
  RESULTS 
  Study  population 
  Four hundred and seventy-nine patients treated with anti-TNF 
agents and 156 treated with placebo in ASSERT or GO–RAISE 
were included. The characteristics of the datasets are presented 
in   table 1  . The mean (SD) ASDAS at baseline was 4.0 (0.8) and 
median ASDAS (IQR) was 3.9 (3.4–4.5).     
  Outcome  predictor  selection 
  Age, CRP, HLA-B27, PGA, BASFI, BASDAI, BASMI, cervi-
cal rotation, tragus to wall distance, intermalleolar distance, 
joint pain/swelling, areas of localised tenderness and morning 
stiffness.    17    BASDAI50 response is deﬁ  ned as a 50% or greater 
improvement in the BASDAI score. 
  Assessment of spondyloarthritis (ASAS) 20 response is an 
improvement of 20% or more in the patient global assessment 
(PGA), patient assessment of pain, Bath ankylosing spondylitis 
functional index (BASFI) score and assessment of inﬂ  ammation. 
ASAS partial remission is achieved when the value of each of 
these domains is less than 2 cm on a 10-cm visual analogue 
scale.    18    
  The ankylosing spondylitis disease activity score (ASDAS) 
measures disease activity state using an algorithm compris-
ing assessment of back pain, morning stiffness duration, joint 
pain/swelling, PGA and C-reactive protein (CRP).    19        20    Clinically 
important and major ASDAS improvements are deﬁ  ned as a 
decrease of 1.1 units or more and 2.0 units or more, respectively. 
ASDAS less than 1.3 is the threshold for an inactive disease 
state.    21    
  The association of the following characteristics at baseline 
with BASDAI50 response and partial remission was studied: 
age, gender, HLA-B27 status, disease duration, CRP, BASFI, Bath 
ankylosing spondylitis metrology index (BASMI) score, chest 
expansion, intermalleolar distance, tragus to wall distance, modi-
ﬁ  ed Schobers index, lateral spinal ﬂ  exion, cervical rotation, PGA, 
pain assessment, BASDAI, inﬂ  ammation score, Berlin enthesitis 
score index and treatment group. MRI, x-rays of the spine and 
peripheral joint counts were not available for the analysis.   
  Statistics 
  Study  population 
  The ASSERT and the GO–RAISE datasets were summarised 
using means±SD and were also combined into a third dataset.   
  Outcome  predictor  selection 
  Predictors of week 12 BASDAI50 response and week 24 partial 
remission were identiﬁ  ed by comparing the values of the afore-
mentioned baseline characteristics between responders and 
non-responders and between remitters and non-remitters using 
Student’s t test and χ  2   tests. Variables that differed at p=0.1 were 
explored further. 
  Multivariate regression and stepwise selection procedures 
were used to narrow the number of predictors. The area under 
the receiver operating characteristics curve (ROC–AUC) and the 
maximum rescaled R  2   were calculated. The ROC–AUC mea-
sures the accuracy of a prediction model as: 90−100% excellent 
prediction; 80−90% good prediction; 70−80% fair prediction; 
60−70% poor prediction and 50−60% failed prediction.    22    The 
R  2   compares how competing models ﬁ  t the dataset.    23    
  Spearman correlation coefﬁ  cients were calculated for continu-
ous baseline characteristics, and associations between variables 
were explored. A variable was selected for the ﬁ  nal prediction 
model if it was retained in stepwise selection in any dataset and 
for either BASDAI50 response or the partial remission model, 
provided it did not have a correlation coefﬁ  cient of 0.4 or greater 
with another variable. Final predictors were categorised into ter-
tiles or according to a clinically relevant threshold in the matrix 
model.   
    Associations of predictors with outcomes 
  Associations of predictor variables with BASDAI50, ASAS20, 
ASDAS clinically important and major improvement, ASAS par-
tial remission and ASDAS inactive disease state were explored 
using OR and 95% CI of outcomes relative to the categor-
ised predictor variables. OR was interpreted as: 1.5 to 1 weak 
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scores but not when other variables were compared (see supple-
mentary table 2, available online only).   
  Age and BASFI score were signiﬁ   cantly higher for HLA-
B27-negative than HLA-B27-positive patients, but numeric 
differences were small and not clinically signiﬁ  cant (see supple-
mentary table 3, available online only). 
  Due to the high correlation between BASMI and BASFI and to 
limit the total number of predictors to six (which is a reasonable 
maximum, considering the total number of patients included 
in the analysis; n=635), BASMI and cervical rotation were not 
retained in the ﬁ  nal model. Age, BASFI, CRP, enthesitis score, 
treatment and HLA-B27 were retained in at least one of the dif-
ferent stepwise selection models and were therefore retained in 
the ﬁ  nal model. 
  BASFI was categorised into 4.5 or less (35%), 4.5–6.5 (31%) 
and over 6.5 (34% of patients). CRP was categorised into 
0.6 mg/dl or less (corresponding with the upper limit of normal 
(ULN) 32%), ULN to 2 mg/dl (34%) and over 2 mg/dl (33%). An 
age cut-off of 40 years yielded the highest ROC–AUC; 46% of 
patients were 40 years old or less and 54% were over 40 years 
old. Enthesitis was present (enthesitis score >0) in 64% and 
absent (enthesitis score 0) in 36%. Additional information lead-
ing to the selection of age and enthesitis categories is provided 
in supplementary table 4, available online only. 
  The ROC–AUC and R  2   of the different models presented in 
  table 2   indicate that the accuracy of the predicted BASDAI50 
response and predicted partial remission was similar when 
models with many predictor variables were compared with 
models with few variables. In addition, they show that the 
ﬁ  nal set of predictors predicts BASDAI50 response and partial 
remission in the three datasets reasonably well. The relation-
ship between the week 12 BASDAI50 response and week 24 
partial remission is shown in supplementary table 5, available 
online only.   
    Associations of predictor variables with outcomes 
  The OR (95% CI) of achieving an outcome relative to the value 
category of a predictor variable is presented in   table 3  .   
  HLA-B27 was more strongly associated with large improve-
ments and disease states (BASDAI50, ASDAS major improve-
ment, ASAS partial remission, ASDAS inactive disease) than 
Berlin enthesitis score and treatment differed signiﬁ  cantly 
(p<0.1) between BASDAI50 responders and non-responders 
and between partial remitters and non-remitters in ASSERT, 
GO–RAISE or the combined dataset (see supplementary table 1, 
available online only). 
  These variables were further investigated. In stepwise mul-
tiple regression analysis (  table 2  ), age, BASFI, enthesitis score, 
CRP, HLA-B27 and treatment were identiﬁ  ed as predictors of 
BASDAI50 response and ASAS partial remission. BASMI and 
cervical rotation were identiﬁ  ed as predictors of partial remis-
sion but not of BASDAI50 response (  table 2  ). High correlation 
was observed between BASMI, its subcomponents and BASFI 
  Table  1         Characteristics at baseline of the ASSERT, the GO–RAISE and 
the combined datasets   
  Variables at baseline   ASSERT   GO–RAISE   Combined 
N 279 356 635
Male (%) 80.6 71.6 75.6
Age (years) 39.8±10.2 39.3±12.1 39.5±11.3
BASDAI score 6.4±1.6 6.7±1.5 6.6±1.5
BASFI score 5.8±2.0 5.1±2.4 5.4±2.2
BASMI score 4.0±2.1 3.5±2.2 3.7±2.1
Cervical rotation (°) 45.8±21.9 48.8±20.3 47.5±21.0
Intermalleolar distance (cm) 95.3±30.6 100.8±24.8 98.3±27.7
Lateral ﬂ  exion (cm) 11.2±11.0 11.0±5.8 11.1±8.5
Tragus to wall distance (cm) 17.0±6.3 14.2±5.7 15.4±6.1
CRP (mg/dl) 2.4±2.7 1.8±2.0 2.1±2.4
Enthesitis, presence of (%) 63.3 63.7 63.5
HLA-B27 positive (%) 87.1 83.4 85.0
PGA (cm) 6.8±1.8 7.0±1.8 6.9±1.8
Concomitant medications for placebo patients
 NSAID  (%) 90.7 92.3 –
  Methotrexate (%) (mean dose (mg/week)) – 19.2 (14.2) –
  Sulphasalazine (%) (mean dose (g/day)) – 30.8 (1.8) –
    Oral corticosteroids (%) (mean dose 
(mg/day))
– 16.7 (7.2) –
  Anti-inﬂ  ammatory/antirheumatic drugs (%) 38.5 – –
      Values are mean±SD for continuous variables or percentages for categorical variables 
unless otherwise speciﬁ  ed. 
  BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing 
spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; 
CRP, C-reactive protein; NSAID, non-steroidal anti-inﬂ  ammatory drug; PGA, patient 
global  assessment.   
  Table  2         Multivariate regression models for BASDAI50 response and ASAS partial remission using variables with p<0.1 on univariate screening, 
stepwise selection and ﬁ  nal selection of variables for both the ASSERT and the GO–RAISE datasets   
 
 ASSERT   GO–RAISE   Combined 
 All   Select   Final   All   Select   Final   All   Select   Final   Final  category 
Age √, x √, x √, x √, x   √, x √, x   √, x >/≤40 years
BASDAI score √, x     √, x     √, x      
BASFI score √, x √√ , x √, x √, x √, x √, x √, x √, x Tertiles
BASMI score √, x x   √, x     √, x      
Cervical rotation √, x     √, x     √, x x    
Intermalleolar distance √, x     √, x     √, x      
Tragus to wall distance √, x     √, x     √, x      
Enthesitis score √, x   √, x √, x x √, x √, x √, x √, x 0/≥1
CRP √, x √, x √, x √, x √√ , x √, x √, x √, x Tertiles
PGA √, x     √, x     √, x      
HLA-B27 √, x   √, x √, x √√ , x √, x √, x √, x +/−
Treatment √, x √, x √, x √, x √, x √, x √, x √, x √, x Anti-TNF/placebo
R  2  0.40, 0.34 0.36, 0.27 0.37, 0.27 0.27, 0.24 0.23, 0.18 0.24, 0.22 0.29, 0.26 0.27, 0.25 0.28, 0.24 0.32, 0.28
ROC–AUC (95% CI) 0.83, 0.84 0.81, 0.80 0.82, 0.80 0.77, 0.78 0.75, 0.74 0.75, 0.77 0.78, 0.79 0.77, 0.79 0.77, 0.78 0.80 (0.76–0.83), 
0.77 (0.73–0.82)
   R  2   and the area under the receiver operating characteristics curve (ROC–AUC) are presented for the different models. √ represents Bath ankylosing spondylitis disease activity index 
(BASDAI) 50, x represents assessment of spondyloarthritis (ASAS) partial remission. R  2   and ROC–AUC values are presented for BASDAI50 response, ASAS partial remission. 
  CRP, C-reactive protein; PGA, patient global assessment.     
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for example, ASDAS major improvement in HLA-B27-positive 
patients aged 40 years or less who had BASFI of 4.5 or less and 
no enthesitis was 81% if their CRP was over 2 mg/dl but only 
22% if their CRP was normal.   
  Differences in response rates exceeding 50% were observed 
when anti-TNF was compared with conventional therapy. The 
robustness of response to anti-TNF therapy is further highlighted 
by   ﬁ  gure 2A–F  , which indicates that almost all subpopulations 
have a NNT of less than ﬁ  ve to achieve small improvements. 
High NNT indicate that large improvements and inactive dis-
ease states are difﬁ  cult to achieve in some subpopulations. The 
ROC–AUC (R  2  ) for the matrix model of ASAS20 response, 
BASDAI50 response, ASAS partial remission, ASDAS clinically 
important and major improvement, and ASDAS inactive disease 
was 0.74 (0.28), 0.80 (0.32), 0.77 (0.28), 0.84 (0.44), 0.84 (0.39) 
and 0.79 (0.25), respectively.     
  Algorithm-based  models 
  The formulae of the models using selected predictor variables 
and/or their interaction terms are presented in supplementary 
table 6, available online only. 
  The values for ROC–AUC and R  2   were very similar to those 
of the matrix models. Comparisons of R  2   show that the model 
to predict week 12 ASDAS ﬁ  tted the combined dataset best. 
Values for R indicate that the association of the algorithm-based 
model with week 12 ASDAS was higher than that with BASDAI. 
Supplementary ﬁ  gures 1a and b (available online only) show the 
predicted versus the observed changes in ASDAS and BASDAI 
scores and also illustrate that the prediction of ASDAS is more 
accurate than the prediction of BASDAI.   
with small improvements (ASAS20, ASDAS clinically impor-
tant improvement). Age was more strongly associated with 
improvement than with disease states. Enthesitis showed weak 
associations with all outcome instruments. The BASFI score was 
strongly associated with disease state and BASDAI50 improve-
ment but less so with ASDAS and ASAS20 improvements. The 
very strong association between CRP and ASDAS improvement 
is striking, albeit reasonable given that CRP is an intrinsic com-
ponent of ASDAS. A strong association was also seen between 
CRP and BASDAI50. Finally, very strong associations between 
anti-TNF therapy and all outcomes were seen with OR ranging 
from 5.8 to 46.5.   
  Matrix  model  construction 
  Matrix models using the six predictor variables were created for 
all outcome instruments ( ﬁ  gure 1A–F  ) and show a good spread of 
outcome rates over the different subpopulations deﬁ  ned by the 
predictor value categories. The strength of associations between 
predictor and outcome instrument is reﬂ  ected in the differences 
between outcome rates in these subpopulations. Differences of 
22% or less were seen when rates of large improvement and dis-
ease states were compared between similar HLA-B27-positive 
versus negative patients. Differences of 14% or less were seen 
when small improvements were compared between genotypes. 
Differences in improvement rates were larger than differences 
in rates of disease state when older and younger patients were 
compared, whereas the association of BASFI led to larger differ-
ences in disease state. Differences in outcome rates related to 
the presence of enthesitis were small. The association of CRP 
with ASDAS improvement led to major differences in outcomes; 
  Table  3         Associations of predictor variables with selected outcome instruments   
 
  ASDAS clinically important 
improvement 3 months    ASAS20 response 3 months 
 OR    Lower 95% CI    Upper 95% CI   OR    Lower 95% CI    Upper 95% CI 
Anti-TNF vs conventional 17.7 10.0 31.3 5.8 3.7 9.0
HLA-27+ vs HLA-27− 1.3 0.7 2.2 1.7 1.1 2.9
Age ≤40 vs >40 years 2.2 1.5 3.4 1.7 1.2 2.4
CRP high vs low 9.3 5.5 16.0 2.2 1.4 3.4
CRP moderate vs low 3.5 2.2 5.7 1.2 0.8 1.9
Berlin enthesitis score 0 vs >0 0.9 0.6 1.3 1.2 0.8 1.6
BASFI low vs high 2.2 1.3 3.6 1.5 1.0 2.4
BASFI moderate vs high 2.2 1.3 3.6 1.9 1.2 3.0
   ASDAS major improvement 3 months   BASDAI50 response 3 months 
  OR   Lower 95% CI   Upper 95% CI   OR   Lower 95% CI   Upper 95% CI 
Anti-TNF vs conventional 14.2 6.5 31.1 8.7 4.9 15.6
HLA-27+ vs HLA-27− 2.4 1.2 4.7 2.5 1.4 4.5
Age ≤40 or >40 years 1.8 1.2 2.9 1.9 1.3 2.8
CRP high vs low 15.0 7.9 28.6 3.6 2.2 5.8
CRP moderate vs low 4.1 2.2 7.8 2.3 1.4 3.7
Berlin enthesitis score 0 vs >0 1.6 1.0 2.5 1.4 1.0 2.1
BASFI low vs high 1.635 0.9 2.8 3.4 2.1 5.5
BASFI moderate vs high 1.4 0.8 2.4 3.0 1.8 4.8
   ASDAS inactive disease 6 months   ASAS partial remission 6 months 
  OR   Lower 95% CI   Upper 95% CI   OR   Lower 95% CI   Upper 95% CI 
Anti-TNF vs conventional 46.5 6.4 339.6 16.8 5.2 54.4
HLA-27+ vs HLA-27− 2.4 1.0 5.5 2.2 1.0 5.0
Age ≤40 or >40 years 1.6 1.0 2.6 1.6 1.0 2.6
CRP high vs low 2.3 1.3 4.2 2.1 1.2 3.7
CRP moderate vs low 1.6 0.9 3.0 1.3 0.8 2.4
Berlin enthesitis score 0 vs >0 1.5 0.9 2.4 1.3 0.8 2.1
BASFI low vs high 3.2 1.7 5.9 4.1 2.2 7.6
BASFI moderate vs high 1.8 1.0 3.5 2.6 1.4 4.8
      ASDAS, ankylosing spondylitis disease activity score; ASAS, assessment of spondyloarthritis; BASDAI, Bath ankylosing spondylitis 
disease activity index; BASFI, Bath ankylosing spondylitis functional index; CRP, C-reactive protein; TNF, tumour necrosis factor.   
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is shown in   ﬁ  gure 3A,B  . The percentage of registry patients 
falling into the different NNT categories for each outcome 
instrument (  ﬁ  gure 2A–F  ) is reported in supplementary table 
7, available online only. For example, for ASDAS clinically 
important improvement, 82.2%, 9.3% and 8.5% of the active 
registry population fell into the NNT less than three, three to 
ﬁ  ve and ﬁ  ve to 10 categories, respectively. NNT greater than 
10 was not observed for this outcome (  ﬁ  gure 2A  ), therefore 
0% of registry patients fell into this category.   
  A detailed comparison of associations between predictors 
and outcomes reported from comparable analyses performed 
in AS populations treated with anti-TNF therapy in clinical 
  practice    10     –       12    is provided in supplementary table 8, available 
online only.     
  DISCUSSION 
  Our analyses show that CRP, HLA-B27 genotype, BASFI, age, 
enthesitis and choice of therapy are independent predictors 
    Distribution of a cross-sectional AS registry population 
over the model 
  Of the 1760 AS patients in the total registry population, 1051 
(59.7%) had an elevated BASDAI score of 4 or greater (ie, the 
active registry population). The distribution of CRP in the 
total/active populations, respectively, was: 56.6%/51.0% for 
patients with CRP less than ULN; 29.8%/33.6% for those 
with a CRP level of ULN to 2 mg/dl; and 13.6%/15.3% for 
those with CRP greater than 2 mg/dl. The distribution of 
BASFI was: 53.9%/32.9% for patients with a score less 
than 4.5; 22.5%/30.4% for those with a score of 4.5–6.5; 
and 23.6%/36.7% for those with a score greater than 6.5. 
Approximately 83% of patients were HLA-B27 positive, and 
approximately 33% of patients were 40 years old or younger 
in both the total and the active populations. Enthesitis was 
present in 16% and 21% of the total and the active registry 
populations, respectively. The percentage of the total and 
the active registry patients falling into each cell of the matrix 
  Figure  1         Matrix presentation of outcome rates of different patient subpopulations (%) deﬁ  ned by the categorised predictor variables: (A) ankylosing 
spondylitis disease activity score (ASDAS) clinically important improvement, (B) ASDAS major improvement, (C) assessment of spondyloarthritis 
(ASAS) partial remission, (D) ASAS 20 response, (E) Bath ankylosing spondylitis disease activity index (BASDAI) 50 response and (F) ASDAS inactive 
disease. BASFI, Bath ankylosing spondylitis functional index; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; NSAID, non-
steroidal anti-inﬂ  ammatory drug; TNF, tumour necrosis factor.       
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  Model  validity 
  The goal of our analysis was to create a practical, evidence-based 
model that can help guide clinicians in making informed treat-
ment choices for AS patients. The predictive variables identiﬁ  ed 
in these randomised studies have been shown to be associated 
of a variety of outcome instruments, and that the combi-
nation of these six variables adequately predicted clinical 
improvement following therapy and subsequent disease 
states in the ASSERT and the GO–RAISE datasets separately 
and combined. 
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  Figure  2         Matrix presentation of numbers needed to treat for one patient to respond to anti-tumour necrosis factor treatment according to different 
outcome instruments at 12 or 24 weeks: (A) ankylosing spondylitis disease activity score (ASDAS) clinically important improvement, (B) ASDAS 
major improvement, (C) assessment of spondyloarthritis (ASAS) partial remission, (D) ASAS 20 response, (E) Bath ankylosing spondylitis disease 
activity index (BASDAI) 50 response, and (F) ASDAS inactive disease. BASFI, Bath ankylosing spondylitis functional index; CRP, C-reactive  protein.    
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  There are, however, several weaknesses of our data indicat-
ing that validation of the model is necessary. The association 
of the enthesitis score with outcomes was not investigated in 
previous reports, and comparisons between anti-TNF and con-
ventional treatment were not performed. Our algorithms and 
models originate from studies designed and powered to show 
the superiority of anti-TNF therapy over placebo, and identify-
ing predictors of response was not a formal endpoint of those 
studies. The blinded, controlled design of the trials may have led 
to outcomes different from those observed in clinical practice, 
with response and remission in other datasets and outside of a 
randomised controlled setting, which lends support to the exter-
nal validity of the model.    8     –      14    
  The associations of age, CRP, HLA-B27 and BASFI with 
BASDAI50 response in ASSERT/GO–RAISE are very similar to 
those in previous reports.    10     –      12      Figure 3   further indicates that 
the 72 subpopulations characterised by the baseline values for 
predictors reasonably represent the AS population in clinical 
practice. This may support the value of our model in daily 
practice. 
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  Figure  3         Cross-sectional application of the ASPECT/Regisponser populations over the matrix grid: percentage of (A) the total registry population 
(including all patients irrespective of Bath ankylosing spondylitis disease activity index (BASDAI) score), and of (B) the active registry population 
(including only patients with a BASDAI score of ≥4) deﬁ  ned by the categorised predictor variables. BASFI, Bath ankylosing spondylitis functional 
index; CRP, C-reactive protein.       
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other clinical characteristics that are associated with response 
and remission in addition to a low BASFI score. For example, 
658 (37.4%) of all registry patients were HLA-B27 positive and 
had CRP elevation greater than ULN; of these, 214 (32.5%) had 
a BASDAI less than 4. These patients have not been studied in 
clinical trials and are currently not recommended for anti-TNF 
therapy. 
  Our data show that somewhat worse outcomes can be 
expected in patients with an elevated enthesitis score. Because of 
the lack of agreement on how enthesitis should be measured,    29    
enthesitis was assessed only as present or absent and was not 
scored in the registries. This explains why enthesitis is present 
in the majority of patients in randomised studies but only in 
a minority of patients in registries. The differences in response 
and remission to anti-TNF therapy were not large when simi-
lar patients with and without enthesitis were compared. As 
anti-TNF agents are very effective in patients with well-deﬁ  ned 
enthesitis,    30    patients with peripheral manifestations having 
worse enthesitis may be a reﬂ  ection of more severe disease in 
general.    31        32    
  HLA-B27-positive patients responded better to anti-TNF 
treatment in our study and in previous reports.    8        12    It is unclear 
whether this is a function of HLA-B27 facilitating earlier and 
correct diagnosis or the disease biology differing in HLA-B27-
positive versus negative AS patients. 
  Age was an independent predictor of outcome in the ASSERT 
study, and signiﬁ  cant differences were seen when age was com-
pared between responders and remitters in the GO–RAISE study 
and the combined dataset. The importance of age in response 
prediction has been shown previously.    8        10        11    Although disease 
duration has been shown to be relevant for outcome prediction,    8    
disease duration was not retained in our dataset because age can 
be more precisely determined than disease duration and may be 
more useful for prediction. 
  Our data conﬁ  rm the association of elevated CRP levels with 
good response to anti-TNF therapy.    9     –      14    As the registry data 
show that AS patients with normal CRP constitute approxi-
mately half the AS population, recognising suitable candidates 
for anti-TNF treatment among such patients may be challeng-
ing. Other inﬂ  ammatory biomarkers and MRI may help in pre-
dicting response to therapy,    14        29    and may be especially useful in 
distinguishing responders from non-responders in patients with 
low CRP.    14        33      
    Subpopulations with robust response to anti-TNF treatment 
  Anti-TNF therapy is recommended for patients who have sus-
tained elevated disease activity despite conventional therapy and 
should be prescribed based on expert opinion.    2    Our prediction 
model may help guide that expert opinion. The data show that 
the continuation of conventional therapy in the face of sustained 
elevated disease activity will be unlikely to result in improve-
ment. The differential responses in ASAS20 and ASDAS clini-
cally important improvement rates from using anti-TNF versus 
continued conventional treatment and the resulting low NNT 
indicate that anti-TNF treatment is a clinically sound choice in 
all subpopulations with elevated disease activity. Given the lack 
of good alternatives, the treating physician should therefore 
consider a deﬁ  ned trial period with an anti-TNF agent if disease 
activity is not controlled with NSAID.    2    Large improvements and 
remission may, however, not be achievable therapeutic goals for 
all patients. 
  In conclusion, our analysis shows that a model combining 
age, HLA-B27 genotype, CRP level, functional status and the 
and other data sources may have led to the development of dif-
ferent models. Finally, the cross-sectional registry data do not 
provide any insight into the model’s ability to predict outcomes 
adequately in daily practice. 
  The predictors retained in the step-wise selection proce-
dures differed between ASSERT and GO–RAISE (  table 2  ), and 
enthesitis was not associated with ASAS20 response (  table 3  , 
supplementary table 6, available online only). As such, some 
ﬁ  nal predictor variables are redundant for certain datasets or for 
certain outcomes. However, independent of the dataset used 
and the outcome instrument predicted, the ROC–AUC of the 
six selected predictors combined remains close to 0.80, indicat-
ing good accuracy of prediction.   
    Comparison of different outcome instruments 
  Interestingly, although ﬁ  nal predictors were selected for their 
ability to predict BASDAI50 response and ASAS partial remis-
sion, these predictors were more accurate in predicting week 
12 ASDAS improvement and inactive disease. Our single com-
ponent analysis shows that this is due to a stronger association 
of CRP and therapy with the ASDAS scoring system (  table 2  ). 
The difference in strength of association between predictors 
and outcome instruments is relevant for trial design in AS. The 
stronger association of anti-TNF therapy with ASDAS than 
with traditional outcomes indicates that the ASDAS scoring 
system may be a more powerful tool than current outcome 
instruments in showing the efﬁ  cacy of biological agents. The 
associations identiﬁ  ed may also improve patient selection in 
studies. 
  The inclusion of CRP as a component in the ASDAS formula 
may explain partly why outcomes assessed with ASDAS were 
very strongly associated with baseline CRP. However, although 
BASFI is a component of ASAS20 response and ASAS partial 
remission criteria, the association between BASFI and these 
outcomes was not as strong as that between CRP and ASDAS 
outcomes. 
  In subpopulations with normal CRP, BASDAI50 response 
and ASAS partial remission rates following anti-TNF treatment 
were higher than ASDAS major improvement and ASDAS inac-
tive disease rates, and absolute differences with response to 
conventional therapy led to higher NNT. Differences between 
ASAS20 response and ASDAS clinically important improvement 
were also present but smaller. This may indicate that outcomes 
in patients with normal CRP may be better assessed with an 
outcome instrument based only on patient-reported outcomes. 
These ﬁ  ndings are in concordance with validation sets of the 
ASDAS in which discrimination of ASDAS was better than that 
of BASDAI in patients with elevated CRP and equal to BASDAI 
in patients with normal CRP.    20      
  Selected  predictors 
  Although BASDAI was not a predictor of response in our data-
sets, it was in previous reports.    8        11    This may be due to a homo-
geneous selection of study patients based on elevated BASDAI 
scores as part of the inclusion criteria. BASFI was retained as 
a predictor in this and previous studies.    10     –      12    The correlation 
between BASDAI and BASFI is relevant for selecting candidates 
for anti-TNF therapy in AS, as shown in the AS registries. The 
proportion of patients in the lowest BASFI category is much 
higher in the total than the active registry population. The high 
correlation between BASFI and BASDAI is due to the exclusion 
of patients with low BASDAI in the active registry population. 
Patients with a BASDAI less than 4, however, may still have 
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presence of enthesitis at baseline enables a good prediction of 
the response to anti-TNF or conventional therapy in AS, as mea-
sured by various outcome instruments. This may help clinicians 
choose more appropriate therapies for patients in daily practice 
and also help improve patient selection and protocol design for 
clinical studies.       
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